Keytruda

Pembrolizumab, the active ingredient in Keytruda, is a monoclonal antibody presented as an injection solution for intravenous infusion for the treatment of various advanced solid tumors and Hodgkin lymphoma. It works by targeting the PD‑1 pathway to enhance the immune system’s ability to fight cancer.

GNH USA supplies Keytruda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality compliance and reliable cold‑chain logistics for global distribution.

Keytruda (pembrolizumab) is a PD‑1 inhibitor used in several solid‑tumor and hematologic cancer pathways.

- Melanoma: improves overall survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer: extends progression‑free survival in advanced cases. - Head and neck squamous cell carcinoma: enhances response rates in recurrent or metastatic settings. - Classical Hodgkin lymphoma: achieves durable remission in relapsed or refractory patients. - Urothelial carcinoma: increases overall survival in metastatic disease. - MSI‑high/dMMR solid tumors: provides benefit across tumor types with high microsatellite instability.

Pembrolizumab may cause a range of immune‑related adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Rash: mild to moderate skin eruptions. - Pruritus: itching without visible rash. - Diarrhea: loose stools, sometimes requiring management. - Nausea: feeling of sickness, may be transient. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pneumonitis: inflammation of lung tissue that can impair breathing. - Colitis: severe inflammation of the colon leading to diarrhea. - Hepatitis: liver inflammation with elevated enzymes. - Endocrinopathies: thyroiditis, adrenal insufficiency, or hypophysitis. - Nephritis: kidney inflammation affecting function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When using Keytruda, clinicians should observe several safety precautions.

- Monitor for immune‑related adverse events: assess organ function regularly. - Baseline screening: evaluate liver, lung, and endocrine status before treatment. - Avoid live vaccines: immunosuppression may increase infection risk. - Pregnancy considerations: potential fetal risk; discuss benefits vs risks with a specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pembrolizumab can interact with other therapies that affect immune function.

Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: may increase toxicity. - Live attenuated vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may diminish therapeutic effect. - Immunosuppressive agents: monitor for reduced efficacy. - Antibiotics for severe infections: watch for overlapping immune effects.